Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $10.49 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.